STOCK TITAN

PROCEPT BioRobotics® to Host 4Q25 Earnings Conference Call on February 24, 2026, and Investor Day on February 25, 2026, in New York City

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

PROCEPT BioRobotics (Nasdaq: PRCT) will report fourth-quarter 2025 results after market close on Tuesday, February 24, 2026, followed by a conference call at 4:30 p.m. ET. The company will host an in-person Investor Day at NASDAQ Headquarters in New York City on Wednesday, February 25, 2026, beginning at 8:00 a.m. ET. Guests are encouraged to register in advance to secure a spot. A live webcast of both events will be available on the company’s Investors website and each webcast will be archived and available for replay for at least 90 days after the event.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

SAN JOSE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the fourth quarter of 2025 after market close on Tuesday, February 24, 2026. The Company’s management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

The Company also announced it will host an in-person investor day event on Wednesday, February 25, 2026, at the NASDAQ Headquarters in New York City beginning at 8:00am Eastern Time. Guests are encouraged to register in advance by clicking HERE. Registration is recommended to secure your spot.

A live webcast of both events, as well as an archived recording, will be available on the “Investors” section of the Company’s website at https://ir.procept-biorobotics.com. Each webcast will be archived and available for replay for at least 90 days after the event.

About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics’ mission is to revolutionize BPH treatment globally in partnership with urologists by delivering best-in-class robotic solutions that positively impact patients and drive value. PROCEPT BioRobotics manufactures the AQUABEAM® and HYDROS® Robotic Systems. The HYDROS Robotic System is the only AI-Powered, robotic technology that delivers Aquablation therapy. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. BPH is the most common prostate disease and impacts approximately 40 million men in the United States.

Important Safety Information
All surgical treatments have inherent and associated side effects. For a list of potential side effects visit https://aquablation.com/safety-information/

Investor Contact:
Matt Bacso
VP, Investor Relations and Business Operations
m.bacso@procept-biorobotics.com


FAQ

When will PROCEPT BioRobotics (PRCT) release its Q4 2025 earnings?

PROCEPT will report Q4 2025 results after market close on February 24, 2026.

What time is the PROCEPT (PRCT) conference call for Q4 2025 results?

The conference call will begin at 4:30 p.m. Eastern Time on February 24, 2026.

When and where is the PROCEPT (PRCT) Investor Day event?

Investor Day is in-person at NASDAQ Headquarters, New York City on February 25, 2026 starting at 8:00 a.m. ET.

How can investors access the PROCEPT (PRCT) webcast and replay?

Both events will be live webcast on the company’s Investors website and archived for replay for at least 90 days.

Do I need to register to attend the PROCEPT (PRCT) Investor Day in person?

Registration is recommended and guests are encouraged to register in advance to secure a spot.

Where can I find the PROCEPT (PRCT) event archive after the Investor Day?

Archived recordings will be available on the company’s Investors website for at least 90 days after the events.
Procept Biorobotics Corp

NASDAQ:PRCT

PRCT Rankings

PRCT Latest News

PRCT Latest SEC Filings

PRCT Stock Data

1.63B
53.40M
4.63%
98.07%
15.04%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
SAN JOSE